TAVR or Surgery for Intermediate-Risk Patients? (GARY Registry)

New findings from the GARY (German Aortic Valve Registry) registry show that intermediate-risk patients with severe aortic stenosis presented significantly higher mortality at 1 year when treated with transcatheter aortic valve replacement (TAVR) rather than with conventional surgery.

 

Results reflect everyday realities, which might include various bias tipping the scales towards one strategy or the other, and which could have contributed to the results.

 

The survival difference favoring surgery shown in the registry persisted even after propensity-score matching, but that does not rule out the presence of many other unadjusted confounding variables.

 

Almost 50,000 patients were enrolled in the GARY registry between January 2011 and December 2013, of whom 22.7% presented intermediate surgical risk (logistic EuroSCORE 10-20%).

 

Overall, 5997 patients who underwent TAVR or isolated valve surgery were included in the analysis.

 

Baseline differences between groups were striking, since patients who underwent TAVR showed higher surgical risk, presented greater age, worse heart failure, more prior myocardial infarction, more atrial fibrillation The most frequent reasons underlying the choice of TAVR over surgery were patient age and frailty.

 

Many of these factors might have affected the rate of all-cause mortality at a year: 8.9% for surgery vs. 16.6% for TAVR (p < 0.001).

 

The decision to choose one strategy over the other was made by a heart team in over 90% of patients, and it is clearly impossible to adjust for medical opinion.

 

Original title: Patients at Intermediate Surgical Risk Undergoing Isolated Interventional or Surgical Aortic Valve Replacement for Severe Symptomatic Aortic Valve Stenosis.

Presenter: Werner N.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...